About: Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model
Creator	Bae, Eun-Hye Chang, Kyu-Tae Kim, Chang-Ung Kim, Doo-Jin Kim, Sang-Hyun Lee, Tae-Young Seo, Sang-Hwan Yoon, Sun-Woo Jeong, Gwin Kim, Young
Source	Elsevier; Medline; PMC
abstract	Abstract Influenza is an acute respiratory disease and a major health problem worldwide. Since mucosal immunity plays a critical role in protection against influenza virus infection, mucosal immunization is considered a promising vaccination route. However, except for live-attenuated vaccines, there are no effective killed or recombinant mucosal influenza vaccines to date. Outer membrane vesicles (OMVs) are nano-sized vesicles produced by gram-negative bacteria, and contain various bacterial components capable of stimulating the immune system of the host. We generated an OMV with low endotoxicity (fmOMV) by modifying the structure of the lipid A moiety of lipopolysaccharide and investigated its effect as an intranasal vaccine adjuvant in an influenza vaccine model. In this model, fmOMV exhibited reduced toll-like receptor 4-stimulating activity and attenuated endotoxicity compared to that of native OMV. Intranasal injection of the vaccine antigen with fmOMV significantly increased systemic antibody and T cell responses, mucosal IgA levels, and the frequency of lung-resident influenza-specific T cells. In addition, the number of antigen-bearing CD103+ dendritic cells in the mediastinal lymph nodes was significantly increased after fmOMV co-administration. Notably, the mice co-immunized with fmOMV showed a significantly higher protection rate against challenge with a lethal dose of homologous or heterologous influenza viruses without adverse effects. These results show the potential of fmOMV as an effective mucosal adjuvant for intranasal vaccines.
has issue date	2017-01-23(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2016.12.025
bibo:pmid	28024958
has license	els-covid
sha1sum (hex)	74cc1a3efb04282e8e89616e58b7749183fc0146
schema:url	https://doi.org/10.1016/j.vaccine.2016.12.025
resource representing a document's title	Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model
has PubMed Central identifier	PMC7115551
has PubMed identifier	28024958
schema:publication	Vaccine
resource representing a document's body	covid:74cc1a3efb04282e8e89616e58b7749183fc0146#body_text
is schema:about of	named entity 'immune system' named entity 'antigen' named entity 'addition' named entity 'mice' named entity 'adjuvant' named entity 'immunization' named entity 'potential' named entity 'produced' covid:arg/74cc1a3efb04282e8e89616e58b7749183fc0146 named entity 'antibody' named entity 'mediastinal' named entity 'influenza' named entity 'vesicles' named entity 'toll-like receptor 4' named entity 'virus' named entity 'IgA' named entity 'generated' named entity 'intranasal' named entity 'mucosal' named entity 'compared' named entity 'frequency' named entity 'mucosal' named entity 'recombinant' named entity 'T cells' named entity 'promising' named entity 'vaccines' named entity 'augment' named entity 'influenza vaccines' named entity 'gram-negative bacteria' named entity 'immunization' named entity 'antibody' named entity 'homologous' named entity 'lung' named entity 'influenza' named entity 'IgA' named entity 'recombinant' named entity 'vesicles' named entity 'influenza virus' named entity 'vaccination' named entity 'antigen' named entity 'influenza vaccine' named entity 'lipid' named entity 'mouse model' named entity 'Outer membrane vesicles' named entity 'structure' named entity 'cholera toxin' named entity 'Victoria' named entity 'vaccine' named entity 'mediastinal lymph node' named entity 'influenza' named entity 'GE Healthcare' named entity 'IgA' named entity 'intranasal' named entity 'cross-protective' named entity 'antigen' named entity 'virus' named entity 'lung' named entity 'log-rank test' named entity 'vaccine delivery' named entity 'Th1' named entity 'immunization' named entity 'Lys' named entity 'inflammatory responses' named entity 'weight loss' named entity 'virus' named entity 'Beckman Coulter' named entity 'splenocytes' named entity 'intranasal' named entity 'adaptive immunity' named entity 'influenza' named entity 'influenza virus' named entity 'OMVs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software